Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nouri Neamati

Showing results (41-50 of 239) with videos related to

Pageof 24
Sort By:
Journal of Medicinal Chemistry|January 20, 2006
HIV integrase inhibitors with nucleobase scaffolds: discovery of a highly potent anti-HIV agentVasu Nair, Guochen Chi, Roger Ptak, et al.
Retrovirology|March 7, 2009
Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitorsErik Serrao, Srinivas Odde, Kavya Ramkumar, et al.
FEBS Letters|March 3, 2007
Single amino acid substitution in HIV-1 integrase catalytic core causes a dramatic shift in inhibitor selectivityLaith Q Al-Mawsawi, Mario Sechi, Nouri Neamati
Journal of Medicinal Chemistry|August 3, 2021
Why All the Fury over Furin?Essam Eldin A Osman, Alnawaz Rehemtulla, Nouri Neamati
Current Drug Targets. Infectious Disorders|December 5, 2002
Structure-based inhibitor design targeting HIV-1 integraseI-Jen Chen, Nouri Neamati, Alexander D MacKerell
Bioinformatics (Oxford, England)|November 22, 2018
TAIJI: approaching experimental replicates-level accuracy for drug synergy predictionHongyang Li, Shuai Hu, Nouri Neamati, et al.
Bioorganic & Medicinal Chemistry Letters|October 4, 2007
Substituted 2-pyrrolinone inhibitors of HIV-1 integraseRaveendra Dayam, Laith Q Al-Mawsawi, Nouri Neamati
Drugs in R&D|May 3, 2007
HIV-1 integrase inhibitors: an emerging clinical realityRaveendra Dayam, Laith Q Al-Mawsawi, Nouri Neamati
Molecular Cancer Therapeutics|March 29, 2013
Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancerShili Xu, Fedora Grande, Antonio Garofalo, et al.
Drug News & Perspectives|December 25, 2010
Are we living in the end of the blockbuster drug era?Bikash Debnath, Laith Q Al-Mawsawi, Nouri Neamati
Pageof 24

Showing results (41-50 of 239) with videos related to

Sort By:
Pageof 24
Journal of Medicinal Chemistry|January 20, 2006
HIV integrase inhibitors with nucleobase scaffolds: discovery of a highly potent anti-HIV agentVasu Nair, Guochen Chi, Roger Ptak, et al.
Retrovirology|March 7, 2009
Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitorsErik Serrao, Srinivas Odde, Kavya Ramkumar, et al.
FEBS Letters|March 3, 2007
Single amino acid substitution in HIV-1 integrase catalytic core causes a dramatic shift in inhibitor selectivityLaith Q Al-Mawsawi, Mario Sechi, Nouri Neamati
Journal of Medicinal Chemistry|August 3, 2021
Why All the Fury over Furin?Essam Eldin A Osman, Alnawaz Rehemtulla, Nouri Neamati
Current Drug Targets. Infectious Disorders|December 5, 2002
Structure-based inhibitor design targeting HIV-1 integraseI-Jen Chen, Nouri Neamati, Alexander D MacKerell
Bioinformatics (Oxford, England)|November 22, 2018
TAIJI: approaching experimental replicates-level accuracy for drug synergy predictionHongyang Li, Shuai Hu, Nouri Neamati, et al.
Bioorganic & Medicinal Chemistry Letters|October 4, 2007
Substituted 2-pyrrolinone inhibitors of HIV-1 integraseRaveendra Dayam, Laith Q Al-Mawsawi, Nouri Neamati
Drugs in R&D|May 3, 2007
HIV-1 integrase inhibitors: an emerging clinical realityRaveendra Dayam, Laith Q Al-Mawsawi, Nouri Neamati
Molecular Cancer Therapeutics|March 29, 2013
Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancerShili Xu, Fedora Grande, Antonio Garofalo, et al.
Drug News & Perspectives|December 25, 2010
Are we living in the end of the blockbuster drug era?Bikash Debnath, Laith Q Al-Mawsawi, Nouri Neamati
Pageof 24